Veppanu (Vepdegestrant)

Veppanu is a medicine used to treat advanced breast cancer that is fed by the hormone estrogen and has a certain gene change. It is taken as a pill by mouth. It works by helping the body break down the estrogen receptor that the cancer uses to grow.

Brand names:Veppanu
Medication

What people taking Veppanu (Vepdegestrant) report

Every report comes from a Lived member, sent anonymously.

Have you tried Veppanu (Vepdegestrant) for Breast Cancer?

NameHow it went

About Veppanu (Vepdegestrant)

What It's For

Vepdegestrant, sold as Veppanu, is a daily pill for adults with advanced or metastatic breast cancer (cancer that cannot be removed with surgery or has spread to other parts of the body). It is approved for one specific type: cancer that is estrogen receptor (ER) positive, meaning estrogen helps drive its growth, and HER2 negative, meaning it does not rely on the HER2 protein. The cancer must also have kept growing after at least one earlier hormone-blocking (endocrine) treatment. There is one more requirement. The cancer must carry a mutation in ESR1, the gene that holds the instructions for the estrogen receptor. A blood test that looks for tumor DNA in the bloodstream, using an FDA-authorized test, shows whether an ESR1 mutation is present. People whose cancers do not show this mutation on testing are not candidates for vepdegestrant. It is one of several options for this situation. Others include fulvestrant (Faslodex), a monthly hormone-blocking injection, and other daily pills that target the estrogen receptor in ESR1-mutated cancer, such as elacestrant (Orserdu) and imlunestrant (Inluriyo). Chemotherapy and other targeted treatments may also be considered, depending on earlier treatment and how the cancer is behaving.

How It Works

Many breast cancers grow because estrogen attaches to the estrogen receptor, a protein inside the cancer cell that switches on growth signals. Most hormone therapies work by lowering estrogen or blocking the receptor. Vepdegestrant takes a different approach: it removes the receptor itself. One end of the molecule grabs the estrogen receptor and the other end grabs part of the cell's own disposal system. This tags the receptor for destruction, and the cell breaks it down. With less receptor present, the cancer cell has less of the signal it depends on to grow. In laboratory studies, this worked on both the normal and the mutated forms of the receptor. Medicines that work this way are called protein degraders.

Dosage & Administration

Vepdegestrant is a tablet taken by mouth once a day with food. The usual dose is 200 mg, and a 100 mg tablet is used when the dose needs to be lowered. Treatment continues for as long as it keeps the cancer under control and side effects stay manageable. Swallow the tablets whole. Do not chew, crush, dissolve or split them, and do not take a tablet that is broken, cracked or damaged. If you miss a dose, or vomit after taking one, do not take another that day. Take the next dose at your usual time the following day, and do not double up. The care team may pause treatment or lower the dose if certain side effects appear, so dose changes should come from them rather than being made on your own.

Side Effects

Tiredness, muscle, joint and bone pain, nausea, lower appetite and constipation are among the most common side effects people notice. Headache, hot flashes and diarrhea occur less often. Several common effects show up only on blood tests: lower white blood cell, red blood cell (hemoglobin) and platelet counts, higher liver enzymes and lower potassium. This is one reason regular blood work is part of treatment. In the main study, most side effects were mild to moderate, and few people stopped the medicine because of them. The most important serious risk is a change in the heart's electrical rhythm, explained below. Get emergency medical help right away if you feel lightheaded or faint, feel dizzy, feel your heart pounding or racing, become short of breath or have chest pain. These can be signs of a dangerous abnormal heart rhythm.

Interactions & Warnings

Vepdegestrant can lengthen the QT interval, a measurement on an electrocardiogram (ECG, a quick test of the heart's electrical activity) that reflects how long the heart takes to reset between beats. A long QT interval raises the risk of a dangerous irregular heartbeat. Before starting, you will have an ECG and blood tests for potassium and magnesium, because low levels of either make this risk higher. The ECG is usually repeated about four weeks in, and more often for people with heart failure, a known long QT problem or other risk factors. Tell your care team about any heart rhythm problems before starting. Many other medicines can also lengthen the QT interval, and taking them together raises the risk further. Examples include some heart rhythm medicines such as amiodarone, the anti-nausea medicine ondansetron and certain antibiotics and antifungal medicines. Some medicines also change how much vepdegestrant is in the blood. Strong blockers of CYP3A, a liver enzyme that breaks the drug down, can raise levels and side effects. These include the antibiotic clarithromycin, antifungal medicines such as itraconazole and voriconazole, and the HIV medicine ritonavir. Medicines that strongly speed up that enzyme lower levels and can make treatment less effective. These include the tuberculosis antibiotic rifampin, the seizure medicines carbamazepine and phenytoin, and the herbal supplement St. John's wort. Avoid grapefruit, grapefruit juice and St. John's wort. Vepdegestrant can also raise levels of some other medicines. Check with your oncologist or pharmacist before starting any new prescription, over-the-counter medicine or supplement. Vepdegestrant can harm a developing baby. If you could become pregnant, you may have a pregnancy test before starting, and you should use effective birth control during treatment and for 2 weeks after the last dose. Men with a partner who could become pregnant should also use effective birth control for the same period. Tell your care team right away if you become pregnant or think you might be. Do not breastfeed during treatment or for 2 weeks after the last dose. Vepdegestrant may also affect fertility in both women and men, which is worth discussing before treatment if future pregnancy matters to you.

What to Expect

Vepdegestrant is a treatment to control advanced breast cancer, not to cure it. In the main study, which compared it with fulvestrant injections in people with ESR1-mutated cancer who had already received a CDK4/6 inhibitor (a type of targeted pill often used with first hormone therapy), the cancer was held in check for a median of about 5 months with vepdegestrant (half of people went longer before it grew, half went less), compared with about 2 months with fulvestrant. About 1 in 5 people with measurable tumors saw them shrink substantially, compared with about 1 in 25 on fulvestrant. Results vary widely, and some people benefit for much longer than the median while others do not respond. When the study was reported, it was too early to know whether vepdegestrant helps people live longer. During treatment, expect regular visits with blood tests, ECGs and periodic scans to check whether the cancer is responding. If the cancer grows or side effects become hard to manage, the care team will talk about changing the dose or moving to another treatment.

Questions to Ask Your Doctor

  1. 1.Has my cancer been tested for an ESR1 mutation, and what did the result show?
  2. 2.How does vepdegestrant compare with fulvestrant, elacestrant or imlunestrant for someone with my treatment history?
  3. 3.How often will I need ECGs and blood tests, and do any of my current medicines affect my heart rhythm risk?
  4. 4.How will we know whether it is working, and what would we try next if it stops?
  5. 5.What do I need to know about birth control, breastfeeding or fertility while I take it?

Last reviewed • Oct 2026

Educational content, not medical advice.